IP Library Granted Patent US 8,202,903
Granted Patent B2
US 8,202,903 · App. 12/296,872 · Granted Jun 19, 2012

Use of aminaphtone for the preparation of a medicament for treating arteriopathies

Assignee: Fondazione IRCCS “CA' Granda—Ospedale Maggiore Policlinico”
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,903
App. No.
12/296,872
Granted
Jun 19, 2012
Kind
B2
Abstract

The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.

Claims (8)

1. A method for the treatment of systemic sclerosis, comprising the step of administering, to a subject in need thereof, a medicament comprising aminaphtone.

2. The method according to claim 1 , wherein said medicament is administered by enteral or parenteral administration.

3. The method according to claim 2 , wherein said medicament administered by enteral administration is administered via the oral route.

4. The method according to claim 1 , wherein said medicament contains a quantity of active ingredient aminaphtone in a quantity between 30 and 150 mg/dose.

5. The method according to claim 3 , wherein said medicament further includes a quantity of excipients selected from: carriers, buffering agents, lubricants, dispersants, flavourings, sweeteners, stabilizers, preservatives, antioxidants commonly used in the pharmaceutical formulation technique.

6. The method according to claim 1 , wherein said medicament is administered in daily dose of between 30 and 350 mg/day.

7. The method according to claim 6 , wherein said medicament is administered in daily dose of between 50 and 300 mg/day.

8. The method according to claim 7 , wherein said medicament is administered in daily dose of between 75 and 250 mg/day.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2013
From: FONDAZIONE IRCCS "CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO
To: LABORATORI BALDACCI S.P.A.
Reel/Frame 030653/0409 →
CHANGE OF NAME Recorded May 13, 2010
From: FONDAZIONE IRCCS ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO DI NATURA PUBBLICA OSPEDALE MAGGIORE POLICLINICO, MANGIAGALLI E REGINA ELENA
To: FONDAZIONE IRCCS "CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO"
Reel/Frame 024381/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2009
From: SCORZA, RAFFAELLA
To: FONDAZIONE IRCCS ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO DI NATURA PUBBLICA OSPEDALE MAGGIORE POLICLINICO, MANGIAGALLI E REGINA ELENA
Reel/Frame 022692/0071 →
Priority Claims (1)
IT MI2006A0712 · Apr 11, 2006 · national
Continuity (1)
Related Publication 20090182045A1 · Jul 16, 2009